12.2.20 | Endometriosis SWHR Urges Congressional Leadership to Prioritize Endometriosis Research Funding
SWHR sent a letter to House and Senate leadership this week in support of endometriosis’ inclusion as an eligible condition […]
12.1.20 | Policy A Call to Improve Women’s Eye Health Through Research, Access, and Education
Successfully improving women’s eye health requires attention to the continuum of health across the life span and awareness of these issues on a societal level.
11.23.20 | Research and Clinical Trials SWHR Comments to FDA on MDUFA Reauthorization for Fiscal Years 2023-2027
The Society for Women’s Health Research (SWHR) submitted comments as a follow-up to the U.S. Food and Drug Administration (FDA) […]
10.16.20 | Alzheimer's Disease SWHR Input to ICER on Assessment of New Alzheimer’s Disease Treatment
SWHR provided open input to the Institute for Clinical and Economic Review (ICER) on contextual considerations surrounding Alzheimer’s disease (AD) […]
10.7.20 | Policy Understanding Disparities in COVID-19 Research and Response
The COVID-19 pandemic has changed lives across the world, but not to the same extent. Vast gender and racial disparities characterize the pandemic in the United States.
10.2.20 | Policy Position Statement: Investment in Women’s Health Research
An Official Position Statement of the Society for Women’s Health Research POSITION The federal government must support research that addresses […]
10.2.20 | Research and Clinical Trials Position Statement: Inclusion of Sex as a Biological Variable in Research
An Official Position Statement of the Society for Women’s Health Research POSITION Research must take into account sex as […]
10.2.20 | Policy Position Statement: Inclusion of Pregnant and Lactating Populations in Research
An Official Position Statement of the Society for Women’s Health Research POSITION In line with our mission to ensure women’s […]
9.9.20 | Research and Clinical Trials SWHR Urges FDA OWH to Prioritize Inclusion of Pregnant Women in Clinical Trials
SWHR signed on to a comment letter from the Coalition to Advance Maternal Therapeutics (CAMT) regarding the inclusion of pregnant […]
9.8.20 | Research and Clinical Trials SWHR Recommendations to FDA OWH on Strategic Priorities
SWHR submitted comments on the U.S. Food and Drug Administration (FDA) Office of Women’s Health’s strategic priorities. SWHR celebrates the […]
